

HAYNES et al  
Appl. No. 10/572,638  
March 1, 2010

RECEIVED  
CENTRAL FAX CENTER

MAR 01 2010

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-115 (Cancelled).

116. (Withdrawn) An isolated protein comprising the sequence of amino acids set forth in Fig. 1A (SEQ ID NO: 1), Fig. 6C (SEQ ID NO: 5), Fig. 6D (SEQ ID NO: 6), Fig. 20C (SEQ ID NO: 28), Fig. 20D (SEQ ID NO: 29), Fig. 26A (SEQ ID NO: 30), Fig. 28B (SEQ ID NO: 33), Fig. 29B (SEQ ID NO: 36), Fig. 30B (SEQ ID NO: 39), Fig. 31B (SEQ ID NO: 42), Fig. 32B (SEQ ID NO: 45), Fig. 33B (SEQ ID NO: 48), Fig. 34B (SEQ ID NO: 51), Fig. 35B (SEQ ID NO: 54), Fig. 36B (SEQ ID NO: 57), Fig. 37B (SEQ ID NO: 60), or Fig. 38B (SEQ ID NO: 63).

117. (Withdrawn) A nucleic acid comprising a nucleotide sequence that encodes the protein according to claim 116.

118. (Withdrawn) The nucleic acid according to claim 117 wherein the protein comprises the sequence of amino acids set forth in Fig. 26A (SEQ ID NO: 30), Fig. 28B (SEQ ID NO: 33), Fig. 29B (SEQ ID NO: 36), Fig. 30B (SEQ ID NO: 39), Fig. 31B (SEQ ID NO: 42), Fig. 32B (SEQ ID NO: 45), Fig. 33B (SEQ ID NO: 48), Fig. 34B (SEQ ID NO: 51), Fig. 35B (SEQ ID NO: 54), Fig. 36B (SEQ ID NO: 57), Fig. 37B (SEQ ID NO: 60), or Fig. 38B (SEQ ID NO: 63).

119. (Cancelled).

120. (Withdrawn) A nucleic acid comprising a nucleotide sequence encoding:

CON6 HIV gp160 protein,

subtype C ancestral HIV envelope protein,

subtype C consensus HIV envelope protein,

HAYNES et al  
Appl. No. 10/572,638  
March 1, 2010

subtype C consensus HIV gag protein,  
subtype C consensus HIV nef protein,  
Group M consensus HIV envelope protein,  
subtype A consensus HIV envelope protein,  
Group M consensus HIV gag protein,  
Group M consensus HIV pol protein,  
Group M consensus HIV nef protein,  
subtype C consensus HIV pol protein,  
subtype B consensus HIV gag protein, or  
subtype B consensus HIV envelope protein

wherein said nucleotide sequence comprises codons optimized for expression in human cells.

121. (Withdrawn) The nucleic acid according to claim 120 wherein said nucleic acid comprises the nucleotide sequence set forth in Fig. 1D (SEQ ID NO: 2), Fig. 6A (SEQ ID NO: 3), Fig. 6B (SEQ ID NO: 4), Fig. 13E (SEQ ID NO: 11), Fig. 13F (SEQ ID NO: 12), Fig. 14B (SEQ ID NO: 14), Fig. 18B (SEQ ID NO: 16), Fig. 19A (SEQ ID NO: 17), Fig. 19B (SEQ ID NO: 18), Fig. 19C (SEQ ID NO: 19), Fig. 19D (SEQ ID NO: 20), Fig. 20A (SEQ ID NO: 25), or Fig. 20B (SEQ ID NO: 26).

122. (Withdrawn) An isolated protein comprising a CF or CFI form of the amino acid sequence set forth in any one of Figs. 39A-127A (SEQ ID NO: 65,66,68,69,73,74,77,78,81,82,85,86,89,90,93,94,97,98,101,102,105,106,109,110,113,115,117,119,121,123,125,127,129,131,133,135,137,139,141,143,145,147,150,152,154,156,158,160,162,164,166,168,170,172,174,176,178,180,182,184,186,188,190,192,194,196,198,200,202,204,206,208

HAYNES et al  
Appl. No. 10/572,638  
March 1, 2010

,210,212,214,216,217,220,222,223,226,228,230,232,233,236,237,240,241,244,245,248,249,252,253,256,257,260).

123. (Withdrawn) A nucleic acid comprising the nucleotide sequence set forth in any one of Figs. 39B-62B (SEQ ID NO: 72,67,70,71,75,76,79,80,83,84,87,88,91,92,95,96,99,100,103,104,107,108,111,112), Figs. 63B-84B (SEQ ID NO: 114,116,118,120,122,124,126,128,130,132,134,136,138,140,142,144,146,148,151,153,155,157,159,161,163), Fig. 65D (SEQ ID NO: 120), Fig. 67D (SEQ ID NO: 126), Fig. 68D (SEQ ID NO: 130), Figs. 85B-106B (SEQ ID NO: 165,167,169,171,173,175,177,179,181,183,185,187,189,191,193,195,197,199,201,203,205,207,209,211,213), Fig. 88D (SEQ ID NO: 173), Fig. 90D (SEQ ID NO: 179), Fig. 92D (SEQ ID NO: 185), Figs. 107B-127B (SEQ ID NO: 215,218,219,221,224,225,227,229,231,234,235,238,239,242,243,246,247,250,251,254,255,258,259,261), Fig. 109D (SEQ ID NO: 221), Fig. 111D (SEQ ID NO: 227) and Fig. 112D (SEQ ID NO: 231).

124. (Withdrawn) A vector comprising the nucleic acid according to any one of claims 117, 120 and 123.

125. (Withdrawn) A composition comprising at least one protein or nucleic acid according to any one of claims 116, 117, 120, 122 and 123 and a carrier.

126. (Withdrawn) A method of inducing an immune response in a mammal comprising administering to said mammal an amount of at least one protein and/or nucleic acid according to any one of claims 116, 117, 120, 122 and 123 sufficient to effect said induction.

127. (Previously Presented) A nucleic acid comprising a codon-optimized nucleotide sequence that encodes the protein encoded by the nucleic acid sequence of Fig. 29C (SEQ ID NO:37).

HAYNES et al  
Appl. No. 10/572,638  
March 1, 2010

128. (Previously Presented) A vector comprising the nucleic acid according to claim 127.
129. (Previously Presented) A composition comprising the nucleic acid according to claim 127 and a carrier.
130. (Previously Presented) A method of inducing an immune response in a mammal comprising administering to said mammal an amount of the nucleic acid according to claim 127 sufficient to effect said induction.
131. (Previously Presented) A nucleic acid comprising the nucleotide sequence set forth in Fig. 29C (SEQ ID NO:37).
132. (Previously Presented) A vector comprising the nucleic acid according to claim 131.
133. (Previously Presented) A composition comprising the nucleic acid according to claim 131 and a carrier.
134. (Previously Presented) A method of inducing an immune response in a mammal comprising administering to said mammal an amount of the nucleic acid according to claim 131 sufficient to effect said induction.